1. Clinical & Scientific Overview
Teriparatide (Recombinant PTH 1-34 Osteoanabolic Injection) (TIP-MED-000251, Reference Code [12.19]) is classified under
Osteoporosis & Bone Metabolism Medicines (Ch 12) as a Recombinant Human Parathyroid Hormone Fragment [rhPTH(1-34)] (Osteoanabolic Bone-Forming Agent).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.19], p. 164): Bonmax-PTH, Forteo, Gemtide, Osteoters — Strengths & Dosage Forms: Pre-filled Multi-Dose Pen Injector / Cartridge: 20 mcg per 80 microlitre dose (600 mcg/2.4 mL or 750 mcg/3 mL pen = 28 doses).
Pre-filled Multi-Dose Pen Injector / Cartridge: 20 mcg per 80 microlitre dose (600 mcg/2.4 mL or 750 mcg/3 mL pen = 28 doses).
3. Mechanism of Action & Pharmacodynamics
Intermittent once-daily pulsatile administration of the biologically active N-terminal 34-amino-acid fragment of PTH preferentially stimulates osteoblast maturation and new trabecular/cortical bone formation over osteoclast resorption.
4. Therapeutic Indications & Evidence-Supported Uses
- Severe postmenopausal, male, or glucocorticoid-induced osteoporosis at very high risk of vertebral/non-vertebral fracture or after bisphosphonate failure
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Adult: 20 mcg SC once daily into the thigh or abdomen (maximum cumulative lifetime duration: 24 months). • Paediatric: CONTRAINDICATED in children and young adults with open epiphyses (osteosarcoma risk).
Administration & Meal Timing: See Administration & Counselling below. | Standard clinical schedule per indication.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Mild-to-moderate CKD: No adjustment. Severe CKD: Caution (prolonged PTH half-life and secondary hyperparathyroidism). • Hepatic: No routine adjustment.
Renal: Mild-to-moderate CKD: No adjustment. Severe CKD: Caution (prolonged PTH half-life and secondary hyperparathyroidism). • Hepatic: No routine adjustment.
Renal: Mild-to-moderate CKD: No adjustment. Severe CKD: Caution (prolonged PTH half-life and secondary hyperparathyroidism). • Hepatic: No routine adjustment.
7. Contraindications, Precautions & High-Risk Warnings
- Contraindications: Pre-existing hypercalcaemia, primary/tertiary hyperparathyroidism, Paget's disease of bone, unexplained elevated alkaline phosphatase, prior external beam or implant skeletal radiation therapy, bone metastases or skeletal malignancies, open epiphyses. • Precautions: Cold-chain biologic (store at 2-8°C; never freeze); first few doses may cause transient orthostatic dizziness/palpitations within 4 hours; after completing the 24-month osteoanabolic course, patients MUST transition immediately to an antiresorptive (Alendronate, Zoledronic acid, or Denosumab) or newly formed bone density will rapidly be lost.
Key Clinical Precautions: Renal: Mild-to-moderate CKD: No adjustment. Severe CKD: Caution (prolonged PTH half-life and secondary hyperparathyroidism). • Hepatic: No routine adjustment.
8. Adverse Effects Profile
- Mild transient hypercalcaemia (4-6 hours post-dose), orthostatic dizziness, leg cramps, nausea, injection-site erythema.
- Symptomatic hypercalcaemia, urolithiasis, theoretical osteosarcoma risk in high-risk bone pathology.
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Digoxin -> transient post-dose hypercalcaemia produced by Teriparatide may predispose to acute digoxin toxicity; Loop diuretics (Furosemide) / Thiazides -> alter renal calcium handling
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Keep pen refrigerated at 2-8°C at all times (remove, inject 20 mcg into thigh/abdomen, and return to fridge immediately—do not keep at room temperature like insulin!); sit or lie down for the first few doses in case of dizziness; discard pen after 28 days of use.
- Meal & Clock Timing Instruction: See Administration & Counselling below. (Standard clinical schedule per indication.)
- Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
- Geriatric Dispensing Pearl: Schedule: Schedule H | NLEM 2022: Non-NLEM | Compendia: IP 2026 / NFI 7th Ed 2026 / CDSCO Schedule H / BNF 90th Ed
Storage, Stability & Dispensing Safeguards: COLD CHAIN MANDATORY (2°C–8°C): Store in a pharmaceutical refrigerator between 2°C and 8°C; DO NOT FREEZE. Protect from light and heat during dispensing.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 12 [12.19] (p. 164)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [12.18]-C166 Risedronate Sodium — Nitrogen-Containing Oral Bisphosphonate (Osteoclast Farnesyl Pyro
- [12.7] Zoledronic Acid (IV Annual Bisphosphonate) & Denosumab (SC RANKL Inhibitor) — Antiresorptive Nitrogen-Containing Bisphosphonates (Alendronate,
- [12.18] Alendronate Sodium & Risedronate (Weekly Oral Bisphosphonates) — Nitrogen-Containing Oral Bisphosphonate (Osteoclast Farnesyl Pyro
- [12.7]-C156 Denosumab (60 mg SC q6m) — Antiresorptive Nitrogen-Containing Bisphosphonates (Alendronate,